Search

Rationale and Objectives: To evaluate the long-term clinical outcomes of magnetic resonance--guided high-intensity focused ultrasound (MR-g HIFU) treatments for symptomatic uterine leiomyomata., Materials and Methods: Patients were recruited for a prospective study for MR-g HIFU treatments of symptomatic leiomyomata, with up to 3-year follow-up. The study was approved by the institutional review board and was Health Insurance Portability and Accountability Act--compliant. Clinical assessments were obtained at 3 months, 6 months, and 1, 2, and 3 years after MR-g HIFU, as well as uterine fibroid symptom severity scores (SSS) and health-related quality of life questionnaires (UFS-QOL). MR imaging was performed at each follow-up to assess the efficacy of the treatment at 6 months, 1 year, 2 years, and 3 years., Results: Fifty-one leiomyomata in 40 patients were treated. All patients were treated within the US Food and Drug Administration guidelines with leiomyomata localized on MR and treated with sonication. The mean baseline volume of treated leiomyomata was 336.9 cm(3). The mean improvement scores for transformed SSS was 47.8 (P < .001) and for tUFS-QOL was 39.8 (P < .001) at 3 years. The mean volume decrease in treated leiomyomata was 32.0% (P < .001), and, in the uterus, the volume decrease was 27.7% (P < .001) at 3 years. There were no long-term complications., Conclusions: Long-term follow-up data from MR-g HIFU treatments show sustained symptomatic relief among enrolled patients. Although the results are preliminary, MR-g HIFU for the treatment of uterine leiomyomata may result in acceptable long-term outcomes at 3 years., (Copyright © 2011 AUR. Published by Elsevier Inc. All rights reserved.)

Purpose: To investigate the comparison between diffusion-weighted imaging (DWI), T2-weighted imaging, (T2WI) and contrast T1-weighted imaging (cT1WI) in uterine leiomyoma following treatment by magnetic resonance imaging-guided, high intensity focused ultrasound surgery (MRg-HIFUS)., Methods: Twenty one patients (45 +/- 5 yrs) with clinical symptoms of uterine leiomyoma (fibroids) were treated by MRg-HIFUS using an integrated 1.5T MRI-HIFUS system. MRI parameters consisted of DWI, T2WI, and T1-weighted fast spoiled gradient echo before and after contrast. The post-MRg-HIFUS treatment volume in the fibroid was assessed by cT1WI and DWI. Trace apparent diffusion coefficient maps were constructed for quantitative analysis. The regions of the treated uterine tissue were defined by a semisupervised segmentation method called the "eigenimage filter," using both cT1WI and DWI. Signal-to-noise ratios were determined for the T2WI pretreatment images. Segmented regions were tested by a similarity index for congruence. Descriptive, regression, and Bland-Altman statistics were calculated., Results: All the patients exhibited heterogeneously increased DWI signal intensity localized in the treated fibroid regions and were colocalized with the cT1WI defined area. The mean pretreatment T2WI signal intensity ratios were T2WI/muscle = 1.8 +/- 0.7 and T2WI/myometrium = 0.7 +/- 0.4. The congruence between the regions was significant, with a similarity of 84% and a difference of 8% between the regions. Regression analyses of the cT1WI and DWI segmented treatment volume were found to be significantly correlated (r2 = 0.94, p < 0.05) with the linear equation, (cT1WI) = 1.1 (DWI)-0.66. There is good agreement between the regions defined by cT1WI and DWI in most of the cases as shown from the Bland-Altman plots., Conclusions: Diffusion-weighted imaging exhibited excellent agreement, congruence, and correlation with the cT1WI-defined region of treatment in uterine fibroid. Therefore, DWI could be useful as an adjunct for assessing treatment of uterine fibroids by MRg-HIFUS.

Purpose: To assess long-term clinical effectiveness of uterine artery embolization (UAE) compared with abdominal myomectomy., Materials and Methods: Women who received UAE (n = 87) or abdominal myomectomy (n = 98) for symptomatic uterine leiomyomata between 2000 and 2002 at a single institution were consecutively enrolled in this study. Patients whose procedures were performed within 5 years before the study were included. Symptom evaluations with symptom severity scores, pregnancy rates, and satisfaction with the procedures were obtained via institutional review board-approved questionnaires. Chart reviews were performed to supplement analyses., Results: The retrospective cohort included 185 patients, of whom long-term follow-up was completed by 89 patients (48.1%), 48 being treated with UAE, and 41 with myomectomy. Follow-up ranged from 50 to 83 months. A higher but not statistically significant number of patients received repeat interventions after abdominal myomectomy (14%) versus UAE (8%; P = .204). Significantly higher symptom severity score improvements were seen in patients treated with UAE versus abdominal myomectomy (34 vs 31; P = .02). UAE recipients were less likely to attempt to get pregnant (P = .02), but those who did had a 66.7% success rate compared with 58.8% for patients who underwent myomectomy. Similar numbers of patients between groups were satisfied with the procedure (P = .57), reported effectiveness of symptom relief (P = .43), and would recommend the procedure to others (P = .37)., Conclusions: UAE results in long-term clinical success with outcomes comparable or superior to those of abdominal myomectomy., (Copyright 2010 SIR. Published by Elsevier Inc. All rights reserved.)

To characterize the histologic range of alterations due to uterine artery embolization with trisacryl gelatin microspheres in gynecologic specimens containing leiomyomas in detail, we report our clinicopathologic experience with 26 cases (longest postuterine artery embolization interval, 1.9 yr). Microspheres were observed in 85% of cases and could be seen up to 1.9 years after embolization. They were mainly present in leiomyomas and nonneoplastic myometrium but could be found in other nontargeted sites, such as the cervix, endometrium, ovaries, and fallopian tubes; however, infarction (present in 96% of cases) was confined to leiomyomas and did not involve other nonneoplastic tissues. The appearance of the infarcts was correlated with time after embolization, and coagulative necrosis/necrosis of indeterminate type was restricted to the early period after uterine artery embolization (before 10 wk postuterine artery embolization) whereas hyaline necrosis was seen predominantly in the late period (mostly after 10 wk, up to 1.9 yr). Of the 14 hysterectomy specimens with microspheres in extravascular spaces (almost all of which were in close proximity to the arteries), pseudoaneurysms were also focally present in 8 (57%) specimens. Microspheres were usually associated with mild inflammatory reactions, which persisted >1 year after embolization but did not become more severe over time. Morphologic and histochemical features of trisacryl gelatin microspheres were compared with other embolization agents, which can also be encountered in surgical specimens [polyvinyl alcohol (PVA) particles and PVA microspheres]. Trisacryl gelatin microspheres were negative with periodic acid-Schiff and orange-pink with Movat stains whereas PVA was positive with periodic acid-Schiff and black with Movat. Our study, the largest histologic analysis to date, confirms and extends the observations of earlier studies of trisacryl gelatin microspheres. In addition, we conclude that, as expected, the histologic appearance of microsphere-induced infarcts is a function of time, similar to healing of infarcts in nongynecologic sites. Pseudoaneurysms are a likely mechanism for the production of microspheres in extravascular spaces. Inflammation associated with microspheres can persist in gynecologic tissues but does not seem to result in the destruction of nontargeted sites. Finally, trisacryl gelatin microspheres can be distinguished from PVA particles and PVA microspheres based on a combination of morphologic features and histochemical stains.

Purpose: To determine the feasibility of using combined proton (1H), diffusion-weighted imaging (DWI), and sodium (23Na) magnetic resonance imaging (MRI) to monitor the treatment of uterine leiomyomata (fibroids)., Materials and Methods: Eight patients with uterine leiomyomata were enrolled and treated using MRI-guided high-intensity frequency ultrasound surgery (MRg-HIFUS). MRI scans collected at baseline and posttreatment consisted of T2-, T1-, and 1H DWI, as well as posttreatment 23Na MRI. The 23Na and 1H MRi were coregistered using a replacement phantom method. Regions of interest in treated and untreated uterine leiomyoma tissue were drawn on 1H MRI and DWI, wherein the tissue apparent diffusion coefficient of water (ADC) and absolute sodium concentrations were measured., Results: Regions of treated uterine tissue were clearly identified on both DWI and 23Na images. The sodium concentrations in normal myometrium tissue were 35.8+/-2.1 mmol (mM), in the fundus; 43.4+/-3.8 mM, and in the bladder; 65.3+/-0.8 mM with ADC in normal myometrium of 2.2+/-0.3x10(-3) mm2/sec. Sodium concentration in untreated leiomyomata were 28+/-5 mM, and were significantly elevated (41.6+/-7.6 mM, P<0.05) after treatment. Apparent diffusion coefficient values in the treated leiomyomata (1.30+/-0.38x10(-3) mm2/sec) were decreased compared to areas of untreated leiomyomata (1.75+/--4048micro-4050micro36x10(-3) mm2/sec; P=0.04)., Conclusion: Multiparametric imaging permits identification of uterine leiomyomata, revealing altered 23Na MRI and DWI levels following noninvasive treatment that provides a mechanism to explore the molecular and metabolic pathways after treatment., (Copyright (c) 2009 Wiley-Liss, Inc.)

Purpose: To assess long-term clinical efficacy of uterine artery embolization (UAE) in young women and the clinical significance of patent anastomoses between uterine and ovarian arteries., Materials and Methods: Consecutive women no older than 39 years of age treated with UAE for symptomatic uterine leiomyomata with at least 3 years of follow-up were included in the study. Analysis includes angiographic images, pre- and postoperative magnetic resonance (MR) images, and symptom evaluations. Clinical evaluation and symptom severity scores (SSSs) were obtained at 6 months and yearly. Leiomyomata volume change, SSS, and repeat intervention rates were compared for patients with and without anastomoses between uterine and ovarian arteries., Results: The study cohort included 87 patients, including 30 white patients (34.4%), 49 black patients (56.3%), and eight patients of other ethnicities (9.2%). Anastomoses were demonstrated in 41 patients (47.1%). Seventy patients (80.5%) completed the long-term follow-up, of whom 35 had an anastomosis (85.4% of the 41 patients with anastomoses) and 35 did not (76.1% of the 46 patients without anastomoses). Mean leiomyoma volume reduction was 49.1% (P = .018), and reduction of uterine volume was 36.0% (P < .001). Mean clinical follow-up duration was 45 months. Overall, 18 of 70 patients (25.7%) underwent repeat interventions, including 13 (37.1%) with anastomoses and five (14.3%) without anastomoses (P = .029). One patient (1.4%) developed natural amenorrheic change in the long term after UAE. Nineteen patients (27.1%) attempted pregnancy after UAE, and 12 patients had 15 pregnancies, with six pregnancies to full term., Conclusions: UAE in young patients achieves significant dominant leiomyoma volume reduction and symptomatic improvements, with overall repeat intervention rates of 25.7% in the long term. Uteroovarian anastomoses in young patients are associated with higher rates of repeat intervention after UAE.

Uterine artery embolization (UAE) for the treatment of symptomatic leiomyomata has shown excellent short-term clinical efficacy and minimal complications, yet recurrences after successful treatments at mid- and long-term follow-up have been reported. Exact etiologies for such recurrences have not been fully understood. We present a case of symptom recurrence with the development of a hypertrophic ovarian artery after successful UAE with polyvinyl alcohol particles, successfully treated with ovarian and repeat UAEs.

The authors evaluated the safety and clinical outcomes of uterine artery embolization (UAE) without the use of conventional iodinated contrast media for symptomatic uterine leiomyomata. Patients underwent UAE with use of CO(2) gas and a gadolinium-based contrast medium. The safety and feasibility of the technique were assessed. Patients were followed up at 24 hours, 1 month, and 6 months after UAE and yearly thereafter. UAE without iodinated contrast medium was attempted in eight patients (mean age, 42.7 years +/- 4.1), and bilateral UAE was successful in all patients. The mean fluoroscopy time was 14.9 minutes. The mean amount of gadolinium-based contrast medium used was 30.6 mL or 0.181 mmol/kg. No major complications were noted. The mean improvement in the symptom severity score was 53.8. The mean reduction in leiomyoma volume was 42%. To date, no repeat interventions have been performed. UAE with CO(2) and a gadolinium-based contrast medium is a viable treatment option for patients with a severe allergy to iodinated contrast media or renal insufficiency.

Objective: To assess several measures of the long-term outcome of magnetic resonance-guided focused ultrasound surgery for symptomatic uterine leiomyomata., Methods: Data on 359 women completing 24-month follow-up in all clinical trials of magnetic resonance-guided focused ultrasound surgery for uterine leiomyomata were analyzed. Quality of life outcomes, measured by the symptom severity score of the Uterine Fibroid Symptoms Quality Of Life Questionnaire were assessed for 24 months after treatment. Clinical endpoints, including uterine shrinkage, the need for additional leiomyoma treatment, and the time to additional leiomyoma treatment, were all assessed. The nonperfused volume ratio after treatment, calculated from the gadolinium-enhanced magnetic resonance imaging after treatment and the best measure of tissue necrosis after treatment, was used to assess outcome based on completeness of leiomyoma ablation., Results: Women undergoing magnetic resonance-guided focused ultrasound surgery for symptomatic uterine leiomyomata have durable symptom relief, as measured by the symptom severity score at 24 months, with significantly greater improvement with more complete ablation (P<.001). Survival analysis demonstrates a significant reduction in the percentage of women undergoing additional leiomyoma treatment (P=.001) in women in the high nonperfused volume group. The mean shrinkage and mean residual nonperfused volume ratio are both significantly above zero at 6 months in the high nonperfused volume group (P<.001). The incidence of adverse events is low. However, for women with minimal treatment, the risk of additional procedures is high., Conclusion: Magnetic resonance-guided focused ultrasound surgery is an effective treatment for uterine leiomyomata and results in sustained symptomatic relief., Level of Evidence: III.

Purpose: To prospectively assess patient response (after 12 months) to magnetic resonance (MR) imaging-guided focused ultrasound surgery in treatment of uterine leiomyomas by using two treatment protocols., Materials and Methods: This prospective clinical trial was approved by institutional review boards and was HIPAA compliant. After giving informed consent, patients with symptomatic leiomyomas were consecutively enrolled and treated at one of five U.S. centers by using an original or a modified protocol. Outcomes were assessed with the symptom severity score (SSS) obtained at baseline and 3, 6, and 12 months after treatment. Adverse events (AEs) were recorded. Statistical analysis included Student t test, Fisher exact test, analysis of covariance, Spearman correlation, and logistic regression., Results: One hundred sixty patients had a mean SSS of 62.1 +/- 16.3 (standard deviation) at baseline, which decreased to 35.5 +/- 19.5 at 3 months (P<.001) and to 32.3 +/- 19.8 at 6 months (P<.001) and was 32.7 +/- 21.0 at 12 months (P<.001). Ninety-six patients (mean age, 46.0 years +/- 4.6) were treated with an original protocol, and 64 (mean age, 45.9 years +/- 3.9) were treated with a modified protocol. Patients in the modified group had a significantly greater SSS decrease at 3 months (P=.037) than those in the original group, and 73% of those in the original group and 91% of those in the modified group reported a significant decrease in SSS (of 10 points or greater) at 12 months. No serious AEs were recorded. Fewer AEs were reported in the modified group than in the original group (25% vs 13% reporting no event). Of evaluable patients, fewer in the modified group chose alternative treatment (28%) than in the original group (37%)., Conclusion: MR imaging-guided focused ultrasound surgery results in symptomatic improvement, sustained to 12 months after treatment. Treatment with a modified protocol results in greater clinical effectiveness and fewer AEs., ((c) RSNA, 2007)

Successful clinical outcomes were obtained after a combined therapy of uterine artery embolization (UAE) and subsequent myomectomy for gigantic subserosal leiomyoma exceeding 1,000 cm3 in volume on a short stalk and multiple intrauterine leiomyomata in young patients who desired fertility and uterine preservation. UAE effectively treated symptomatic multiple intramural and submucosal leiomyomata for menorrhagia symptoms, which also facilitated uncomplicated subsequent myomectomy with devascularized gigantic leiomyoma for the treatment of bulk symptoms.

Purpose: To assess the prevalence of anastomoses between uterine and ovarian arteries on angiography and their impact on changes in basal follicle-stimulating hormone (FSH) level after uterine artery embolization (UAE)., Materials and Methods: Consecutive premenopausal women who underwent UAE for symptomatic uterine leiomyomata according to a uniform embolization technique with tris-acryl gelatin microspheres at a single institution were included in the study. Basal FSH levels before UAE and 6 months after UAE were compared for patients with and without anastomoses between uterine and ovarian arteries on angiography., Results: Among 124 patients included in the study (mean age, 43.1+/-5.7 years), patent anastomoses between the uterine and ovarian arteries were detected by angiography in 55 patients (44.4%). Overall, 11.3% of 124 patients showed an increase in basal serum FSH level of greater than 20 mIU/mL after UAE. In patients with utero-ovarian anastomoses, 18.2% showed an increase of greater than 20 mIU/mL after UAE, compared with 5.8% of patients without such anastomoses (P=.03). Mean basal FSH increase after UAE in patients with anastomoses was 8.4+/-20.2 mIU/mL, compared with 2.7+/-10.6 mIU/mL in patients without anastomoses (P=.047). Among patients with anastomoses, the 50- to 54-year age group had the highest percentage of patients with an FSH increase greater than 20 mIU/mL (50.0%) after UAE, followed by patients in the 45- to 49-year age group (15.4%)., Conclusions: Angiographically detected anastomoses between the uterine artery and the ovarian artery are not uncommon. UAE in patients with anastomoses is associated with a greater risk of significant increase of basal FSH level than in UAE in patients without anastomoses. The pathophysiologic processes resulting in change of FSH level may be a reflection of diminished ovarian function, but further study is warranted to delineate the precise mechanism.

Objective: To assess outcomes at 6 and 12 months after magnetic resonance-guided focused ultrasound surgery (MRgFUS) for symptomatic uterine leiomyomas., Design: Multicenter clinical trial., Setting: Academic medical centers., Patient(s): Premenopausal women with symptomatic uterine leiomyomas and no plans for future pregnancy (n = 109 at 6 months and n = 82 at 12 months)., Intervention(s): A single treatment session of MRgFUS for uterine fibroids., Main Outcome Measure(s): Reduction in fibroid symptoms as measured by the symptom severity score (SSS) of the Uterine Fibroid Quality-of-Life Instrument (UFS-QOL), the only validated measure of leiomyoma symptomatology. A 10-point reduction in the SSS was selected as the targeted improvement., Result(s): Seventy-one percent of women undergoing MRgFUS reached the targeted symptom reduction at 6 months, and 51% reached this at 12 months. The magnitude of improvement in SSS was greater than predicted, with subjects having a mean decrease of 39% and 36% at 6 and 12 months, respectively. This paralleled the improvement seen using the short form-36 instrument. A modest volume reduction similar in magnitude to the treated volume was seen. The incidence of adverse events was low., Conclusion(s): MRgFUS treatment results in short-term symptom reduction for women with symptomatic uterine leiomyomas with an excellent safety profile.

Purpose: To prospectively determine the feasibility of using diffusion-weighted (DW) imaging and apparent diffusion coefficient (ADC) mapping before (baseline) and after treatment and at 6-month follow-up to monitor magnetic resonance (MR) image-guided focused ultrasound surgical ablation of uterine fibroids., Materials and Methods: Informed consent was obtained from patients before treatment with our study protocol, as approved by the institutional review board, and the study complied with the Health Insurance Portability and Accountability Act. Fourteen patients (mean age, 46 years +/- 5 [standard deviation]) who underwent DW imaging were enrolled in this study, and 12 of 14 completed the inclusive MR examination with DW imaging at 6-month follow-up. Treatment was performed by one radiologist with a modified MR image-guided focused ultrasound surgical system coupled with a 1.5-T MR imager. Pre- and posttreatment and 6-month follow-up MR images were obtained by using phase-sensitive T1-weighted fast spoiled gradient-recalled acquisition, T1-weighted contrast material-enhanced, and DW imaging sequences. Total treatment time was 1-3 hours. Trace ADC maps were constructed for quantitative analysis. Regions of interest localized to areas of hyperintensity on DW images were drawn on postcontrast images, and quantitative statistics were obtained from treated and nontreated uterine tissue before and after treatment and at 6-month follow-up. Statistical analysis was performed with analysis of variance. Differences with P < .05 were considered statistically significant., Results: T1-weighted contrast-enhancing fibroids selected for treatment had no hyperintense or hypointense signal intensity changes on the DW images or ADC maps before treatment. Considerably increased signal intensity changes that were localized within the treated areas were noted on DW images. Mean baseline ADC value in fibroids was 1504 mm(-6)/sec2 +/- 290. Posttreatment ADC values for nontreated fibroid tissue (1685 mm(-6)/sec2 +/- 468) differed from posttreatment ADC values for fibroid tissue (1078 mm(-6)/sec2 +/- 293) (P = .001). A significant difference (P < .001) between ADC values for treated (1905 mm(-6)/sec2 +/- 446) and nontreated (1437 mm(-6)/sec2 +/- 270) fibroid tissue at 6-month follow-up was observed., Conclusion: DW imaging and ADC mapping are feasible for identification of ablated tissue after focused ultrasound treatment of uterine fibroids., (Copyright RSNA, 2005)

Our objective was to evaluate the role of echoplanar diffusion-weighted imaging (DWI) and apparent diffusion coefficient (ADC) maps in the assessment of response of uterine fibroids and myometrium to uterine fibroid embolization (UFE). We evaluated 32 fibroids in 11 patients treated with UFE. Treated lesions had low ADC values compared to untreated lesions. Furthermore, ADC values of the myometrium did not significantly change after embolization, suggesting maintained myometrial viability after embolization. DWI and ADC maps, by providing functional information at a cellular level, may serve as imaging tools for assessing treatment response after UFE.

Objective: The purpose of this study was to explore our hypothesis that MRI-guided focused ultrasound therapy for the treatment of uterine fibroids will lead to a significant reduction in symptoms and improvement in quality of life. We describe focused ultrasound therapy applications and the method for monitoring the thermal energy deposited in the fibroids, including the MRI parameters required, in a prospective review of 108 treatments., Materials and Methods: Patients presenting with symptomatic uterine fibroids who attained a minimal symptom severity score and who would otherwise have been offered a hysterectomy were recruited. Thermal lesions were created within target fibroids using an MRI-guided focused ultrasound therapy system. The developing lesion was monitored using real-time MR thermometry, which was used to assess treatment outcome in real time to change treatment parameters and achieve the desired outcome. Fibroid volume, fibroid symptoms, and quality-of-life scores were measured before treatment and 6 months after treatment. Adverse events were actively monitored and recorded., Results: In this study, 79.3% of women who had been treated reported a significant improvement in their uterine fibroid symptoms on follow-up health-related quality-of-life questionnaires, which supports our hypothesis. The mean reduction in fibroid volume at 6 months was 13.5%, but nonenhancing volume (mean, 51 cm(3)) remained within the treated fibroid at 6 months., Conclusion: This early description of MRI-guided focused ultrasound therapy treatment of fibroids includes follow-up data and shows that, although the volume reduction is moderate, it correlates with treatment volume and the symptomatic response to this treatment is encouraging.

Purpose: To investigate the comparison between diffusion-weighted imaging (DWI), T2-weighted imaging, (T2WI) and contrast T1-weighted imaging (cT1WI) in uterine leiomyoma following treatment by magnetic resonance imaging-guided, high intensity focused ultrasound surgery (MRg-HIFUS). Methods: Twenty one patients (45±5 yrs) with clinical symptoms of uterine leiomyoma (fibroids) were treated by MRg-HIFUS using an integrated 1.5T MRI-HIFUS system. MRI parameters consisted of DWI, T2WI, and T1-weighted fast spoiled gradient echo before and after contrast. The post-MRg-HIFUS treatment volume in the fibroid was assessed by cT1WI and DWI. Trace apparent diffusion coefficient maps were constructed for quantitative analysis. The regions of the treated uterine tissue were defined by a semisupervised segmentation method called the “eigenimage filter,” using both cT1WI and DWI. Signal-to-noise ratios were determined for the T2WI pretreatment images. Segmented regions were tested by a similarity index for congruence. Descriptive, regression, and Bland–Altman statistics were calculated. Results: All the patients exhibited heterogeneously increased DWI signal intensity localized in the treated fibroid regions and were colocalized with the cT1WI defined area. The mean pretreatment T2WI signal intensity ratios were T2WI/muscle=1.8±0.7 and T2WI/myometrium=0.7±0.4. The congruence between the regions was significant, with a similarity of 84% and a difference of 8% between the regions. Regression analyses of the cT1WI and DWI segmented treatment volumes were found to be significantly correlated (r2=0.94, p<0.05) with the linear equation, (cT1WI)=1.1(DWI)-0.66. There is good agreement between the regions defined by cT1WI and DWI in most of the cases as shown from the Bland–Altman plots. Conclusions: Diffusion-weighted imaging exhibited excellent agreement, congruence, and correlation with the cT1WI-defined region of treatment in uterine fibroid. Therefore, DWI could be useful as an adjunct for assessing treatment of uterine fibroids by MRg-HIFUS. [ABSTRACT FROM AUTHOR]